Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

Executive Summary

Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.
Advertisement

Related Content

US FDA Guidance Production May Be Slowed By New OMB Review Requirement
Generic Industry Market Forces May Impact GDUFA III Talks
Biosimilars: US FDA Asked To Clarify Thinking On Pediatric Studies, Indication Carve-Outs
BsUFA III: Industry Eyes Streamlined Review Of New Indications, Phased Review Process
Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says
Biosimilar Labeling Carve-Out Turned Erelzi's Psoriatic Arthritis, Plaque Psoriasis Uses Into 'Another Indication'
Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel